Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.48 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10682348 | 0.88 | KMT2A (0.51) | KMT2AL3MBTL1NPFFR1NPFFR2SIGMAR1 | |
| SCHEMBL803459 | 0.82 | ACHE (0.67) | ACHE | |
| SCHEMBL9091685 | 0.81 | OPRM1 (0.55) | KMT2AL3MBTL1SIGMAR1DRD2 | |
| SCHEMBL14290582 | 0.81 | OPRM1 (0.55) | KMT2AL3MBTL1SIGMAR1DRD2 | |
| SCHEMBL30500906 | 0.81 | NPFFR1 (0.50) | KMT2AL3MBTL1NPFFR1NPFFR2SIGMAR1 | |
| SCHEMBL6535932 | 0.81 | KMT2A (0.49) | KMT2AL3MBTL1NPFFR1NPFFR2SIGMAR1 | |
| SCHEMBL29604592 | 0.81 | SIGMAR1 (0.48) | KMT2AL3MBTL1NPFFR1NPFFR2SIGMAR1 | |
| SCHEMBL29604392 | 0.81 | SIGMAR1 (0.48) | KMT2AL3MBTL1NPFFR1NPFFR2SIGMAR1 | |
| SCHEMBL5969188 | 0.80 | ACHE (0.60) | ACHEBCHEDRD2 | |
| SCHEMBL30049396 | 0.78 | ACHE (0.58) | NPFFR1NPFFR2ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| WO-2015150557-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | VPS26B, VPS4B, VPS28 | KMT2A 3748/4885L3MBTL1 4493/4885NPFFR1 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.